文献速递消化系统肿瘤

雷莫西尤单抗进展后联合伊立替康治疗雷莫西尤单抗难治性晚期胃癌的随机III期试验:RINDBeRG试验

Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial.
PubMed 文献 · J Clin Oncol · 2025-05-23

RINDBeRG试验在既往含雷莫西尤单抗方案治疗期间进展的晚期或复发性胃癌或胃食管癌患者中,比较雷莫西尤单抗联合伊立替康与伊立替康单药作为三线或后线治疗的疗效与安全性。结果显示联合组中位总生存期9.4个月、单药组8.5个月,调整后HR 0.91(95%CI 0.74~1.12;P=.49),总生存期无显著获益;无进展生存期和疾病控制率联合组更优。

要点

  • 联合组与单药组中位OS分别为9.4个月与8.5个月,调整后HR 0.91(95%CI 0.74~1.12;P=.49),无显著获益。
  • 联合组中位PFS 3.8个月优于单药组2.8个月(HR 0.72;95%CI 0.59~0.89;P=.002)。
  • 联合组疾病控制率64.4%优于单药组52.1%(P=.03),联合治疗不良事件可控。

核心结论

  • 在含雷莫西尤单抗化疗期间进展的晚期或复发性胃或胃食管癌患者中,伊立替康联合雷莫西尤单抗较伊立替康单药未在总生存期上提供显著优势。

研究设计与样本

  • 随机III期试验,2017年2月至2022年8月在日本纳入402例20岁及以上、含雷莫西尤单抗化疗期间进展的晚期或复发性胃或胃食管癌患者,随机分为雷莫西尤单抗联合伊立替康组(n=202)与伊立替康单药组(n=200)。
  • 主要终点为总生存期,预设HR为0.77(把握度80%,单侧显著性水平0.05);次要终点包括无进展生存期、缓解率、疾病控制率和安全性。

主要发现

  • 联合组中位总生存期9.4个月,单药组8.5个月,调整后HR 0.91(95%CI 0.74~1.12;P=.49)。
  • 联合组中位无进展生存期3.8个月,单药组2.8个月(HR 0.72;95%CI 0.59~0.89;P=.002)。
  • 联合组疾病控制率64.4%,单药组52.1%(P=.03)。
  • 联合治疗的不良事件可控。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Continuous use of antiangiogenic agents has demonstrated survival benefits in various cancers. This trial aimed to compare the efficacy and safety of ramucirumab plus irinotecan with irinotecan monotherapy as a third- or later-line treatment for patients with advanced or recurrent gastric or gastroesophageal cancer (AGC) that has progressed on previous ramucirumab-based chemotherapy. METHODS: Patients age 20 years and older with AGC, who had experienced disease progression during ramucirumab-based chemotherapy, were randomly assigned to receive either ramucirumab plus irinotecan or irinotecan monotherapy. The primary end point was overall survival (OS) expecting a hazard ratio (HR) of 0.77 (a power of 80% and a significance level of one-sided 0.05). Secondary end points included progression-free survival (PFS), response rate, disease control rate (DCR), and safety. RESULTS: Between February 2017 and August 2022, 402 patients in Japan were randomly assigned to receive ramucirumab plus irinotecan (n = 202) or irinotecan monotherapy (n = 200). The median OS was 9.4 months in the combination arm and 8.5 months in the monotherapy arm, with an adjusted HR of 0.91 (95% CI, 0.74 to 1.12; P = .49). PFS was improved (median, 3.8 v 2.8 months; HR, 0.72 [95% CI, 0.59 to 0.89]; P = .002), while the DCR was significantly better (64.4% v 52.1%; P = .03) with the combination therapy. The adverse events of the combination therapy were manageable. CONCLUSION: Adding ramucirumab to irinotecan does not provide a significant advantage in OS over irinotecan alone in patients with AGC who have progressed during ramucirumab-containing chemotherapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Sakai D, Kadowaki S, Kawabata R, et al. Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial. J Clin Oncol. 2025. PMID: 40408613. doi:10.1200/JCO.24.01119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。